ID   NHLC1_HUMAN             Reviewed;         395 AA.
AC   Q6VVB1; Q3SYB1; Q5VUK7; Q6IMH1;
DT   19-JUL-2004, integrated into UniProtKB/Swiss-Prot.
DT   19-JUL-2004, sequence version 2.
DT   10-MAY-2017, entry version 128.
DE   RecName: Full=E3 ubiquitin-protein ligase NHLRC1;
DE            EC=2.3.2.27;
DE   AltName: Full=Malin;
DE   AltName: Full=NHL repeat-containing protein 1;
DE   AltName: Full=RING-type E3 ubiquitin transferase NHLRC1 {ECO:0000305};
GN   Name=NHLRC1; Synonyms=EPM2B;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], SUBCELLULAR LOCATION, TISSUE SPECIFICITY,
RP   VARIANTS EPM2 SER-26; SER-33; ALA-69; PRO-87; ASN-146 AND PRO-302, AND
RP   VARIANT LEU-111.
RX   PubMed=12958597; DOI=10.1038/ng1238;
RA   Chan E.M., Young E.J., Ianzano L., Munteanu I., Zhao X.,
RA   Christopoulos C.C., Avanzini G., Elia M., Ackerley C.A., Jovic N.J.,
RA   Bohlega S., Andermann E., Rouleau G.A., Delgado-Escueta A.V.,
RA   Minassian B.A., Scherer S.W.;
RT   "Mutations in NHLRC1 cause progressive myoclonus epilepsy.";
RL   Nat. Genet. 35:125-127(2003).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=14574404; DOI=10.1038/nature02055;
RA   Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L.,
RA   Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E.,
RA   Gilbert J.G.R., Clamp M.E., Bethel G., Milne S., Ainscough R.,
RA   Almeida J.P., Ambrose K.D., Andrews T.D., Ashwell R.I.S.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Banerjee R., Barker D.J.,
RA   Barlow K.F., Bates K., Beare D.M., Beasley H., Beasley O., Bird C.P.,
RA   Blakey S.E., Bray-Allen S., Brook J., Brown A.J., Brown J.Y.,
RA   Burford D.C., Burrill W., Burton J., Carder C., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V.,
RA   Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J.,
RA   Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E.,
RA   Ellington A.E., Evans K.A., Faulkner L., Francis M.D., Frankish A.,
RA   Frankland J., French L., Garner P., Garnett J., Ghori M.J.,
RA   Gilby L.M., Gillson C.J., Glithero R.J., Grafham D.V., Grant M.,
RA   Gribble S., Griffiths C., Griffiths M.N.D., Hall R., Halls K.S.,
RA   Hammond S., Harley J.L., Hart E.A., Heath P.D., Heathcott R.,
RA   Holmes S.J., Howden P.J., Howe K.L., Howell G.R., Huckle E.,
RA   Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M., Joy A.A.,
RA   Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K., Langford C.,
RA   Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R., Lloyd D.M.,
RA   Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M.,
RA   Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K.,
RA   McMurray A., Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T.,
RA   Novik K.L., Oliver K., Overton-Larty E.K., Parker A., Patel R.,
RA   Pearce A.V., Peck A.I., Phillimore B.J.C.T., Phillips S., Plumb R.W.,
RA   Porter K.M., Ramsey Y., Ranby S.A., Rice C.M., Ross M.T., Searle S.M.,
RA   Sehra H.K., Sheridan E., Skuce C.D., Smith S., Smith M., Spraggon L.,
RA   Squares S.L., Steward C.A., Sycamore N., Tamlyn-Hall G., Tester J.,
RA   Theaker A.J., Thomas D.W., Thorpe A., Tracey A., Tromans A., Tubby B.,
RA   Wall M., Wallis J.M., West A.P., White S.S., Whitehead S.L.,
RA   Whittaker H., Wild A., Willey D.J., Wilmer T.E., Wood J.M., Wray P.W.,
RA   Wyatt J.C., Young L., Younger R.M., Bentley D.R., Coulson A.,
RA   Durbin R.M., Hubbard T., Sulston J.E., Dunham I., Rogers J., Beck S.;
RT   "The DNA sequence and analysis of human chromosome 6.";
RL   Nature 425:805-811(2003).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT LEU-111.
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   FUNCTION, INTERACTION WITH EPM2A, DOMAIN RING, CHARACTERIZATION OF
RP   VARIANT EPM2 PRO-302, AND MUTAGENESIS OF GLU-280.
RX   PubMed=15930137; DOI=10.1073/pnas.0503285102;
RA   Gentry M.S., Worby C.A., Dixon J.E.;
RT   "Insights into Lafora disease: malin is an E3 ubiquitin ligase that
RT   ubiquitinates and promotes the degradation of laforin.";
RL   Proc. Natl. Acad. Sci. U.S.A. 102:8501-8506(2005).
RN   [5]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH AGL.
RX   PubMed=17908927; DOI=10.1101/gad.1553207;
RA   Cheng A., Zhang M., Gentry M.S., Worby C.A., Dixon J.E., Saltiel A.R.;
RT   "A role for AGL ubiquitination in the glycogen storage disorders of
RT   Lafora and Cori's disease.";
RL   Genes Dev. 21:2399-2409(2007).
RN   [6]
RP   FUNCTION.
RX   PubMed=18070875; DOI=10.1074/jbc.M708712200;
RA   Worby C.A., Gentry M.S., Dixon J.E.;
RT   "Malin decreases glycogen accumulation by promoting the degradation of
RT   protein targeting to glycogen (PTG).";
RL   J. Biol. Chem. 283:4069-4076(2008).
RN   [7]
RP   FUNCTION, AND COMPLEX FORMATION WITH EPM2A AND HSP70.
RX   PubMed=19036738; DOI=10.1093/hmg/ddn398;
RA   Garyali P., Siwach P., Singh P.K., Puri R., Mittal S., Sengupta S.,
RA   Parihar R., Ganesh S.;
RT   "The malin-laforin complex suppresses the cellular toxicity of
RT   misfolded proteins by promoting their degradation through the
RT   ubiquitin-proteasome system.";
RL   Hum. Mol. Genet. 18:688-700(2009).
RN   [8]
RP   INTERACTION WITH PRDM8.
RX   PubMed=22961547; DOI=10.1093/brain/aws205;
RA   Turnbull J., Girard J.M., Lohi H., Chan E.M., Wang P., Tiberia E.,
RA   Omer S., Ahmed M., Bennett C., Chakrabarty A., Tyagi A., Liu Y.,
RA   Pencea N., Zhao X., Scherer S.W., Ackerley C.A., Minassian B.A.;
RT   "Early-onset Lafora body disease.";
RL   Brain 135:2684-2698(2012).
RN   [9]
RP   FUNCTION.
RX   PubMed=23624058; DOI=10.1016/j.biocel.2013.04.019;
RA   Rubio-Villena C., Garcia-Gimeno M.A., Sanz P.;
RT   "Glycogenic activity of R6, a protein phosphatase 1 regulatory
RT   subunit, is modulated by the laforin-malin complex.";
RL   Int. J. Biochem. Cell Biol. 45:1479-1488(2013).
RN   [10]
RP   VARIANTS EPM2 MET-153; ARG-160; ARG-219; ASN-245 AND LYS-253, AND
RP   VARIANT LEU-111.
RX   PubMed=16021330; DOI=10.1007/s10038-005-0263-7;
RA   Singh S., Suzuki T., Uchiyama A., Kumada S., Moriyama N., Hirose S.,
RA   Takahashi Y., Sugie H., Mizoguchi K., Inoue Y., Kimura K.,
RA   Sawaishi Y., Yamakawa K., Ganesh S.;
RT   "Mutations in the NHLRC1 gene are the common cause for Lafora disease
RT   in the Japanese population.";
RL   J. Hum. Genet. 50:347-352(2005).
RN   [11]
RP   VARIANTS EPM2 GLN-67; TYR-68; ASN-198; ALA-233; HIS-264;
RP   294-VAL-LYS-295 DEL AND ALA-308.
RX   PubMed=15781812; DOI=10.1212/01.WNL.0000154519.10805.F7;
RA   Gomez-Abad C., Gomez-Garre P., Gutierrez-Delicado E., Saygi S.,
RA   Michelucci R., Tassinari C.A., Rodriguez de Cordoba S.,
RA   Serratosa J.M.;
RT   "Lafora disease due to EPM2B mutations: a clinical and genetic
RT   study.";
RL   Neurology 64:982-986(2005).
RN   [12]
RP   VARIANTS EPM2 ARG-22; PRO-126 AND PRO-279, AND CHARACTERIZATION OF
RP   VARIANTS EPM2 ARG-22; PRO-126 AND PRO-279.
RX   PubMed=18311786; DOI=10.1002/humu.20737;
RA   Singh S., Satishchandra P., Shankar S.K., Ganesh S.;
RT   "Lafora disease in the Indian population: EPM2A and NHLRC1 gene
RT   mutations and their impact on subcellular localization of laforin and
RT   malin.";
RL   Hum. Mutat. 29:E1-12(2008).
RN   [13]
RP   VARIANTS EPM2 TYR-46; ALA-69; ASN-146 AND PRO-261, CHARACTERIZATION OF
RP   VARIANTS EPM2 TYR-46; ALA-69; ASN-146 AND PRO-261, FUNCTION,
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH EPM2A.
RX   PubMed=21505799; DOI=10.1007/s00109-011-0758-y;
RA   Couarch P., Vernia S., Gourfinkel-An I., Lesca G., Gataullina S.,
RA   Fedirko E., Trouillard O., Depienne C., Dulac O., Steschenko D.,
RA   Leguern E., Sanz P., Baulac S.;
RT   "Lafora progressive myoclonus epilepsy: NHLRC1 mutations affect
RT   glycogen metabolism.";
RL   J. Mol. Med. 89:915-925(2011).
CC   -!- FUNCTION: E3 ubiquitin-protein ligase. Together with the
CC       phosphatase EPM2A/laforin, appears to be involved in the clearance
CC       of toxic polyglucosan and protein aggregates via multiple
CC       pathways. In complex with EPM2A/laforin and HSP70, suppresses the
CC       cellular toxicity of misfolded proteins by promoting their
CC       degradation through the ubiquitin-proteasome system (UPS).
CC       Ubiquitinates the glycogen-targeting protein phosphatase subunits
CC       PPP1R3C/PTG and PPP1R3D in a laforin-dependent manner and targets
CC       them for proteasome-dependent degradation, thus decreasing
CC       glycogen accumulation. Polyubiquitinates EPM2A/laforin and
CC       ubiquitinates AGL and targets them for proteasome-dependent
CC       degradation. Also promotes proteasome-independent protein
CC       degradation through the macroautophagy pathway.
CC       {ECO:0000269|PubMed:15930137, ECO:0000269|PubMed:17908927,
CC       ECO:0000269|PubMed:18070875, ECO:0000269|PubMed:19036738,
CC       ECO:0000269|PubMed:21505799, ECO:0000269|PubMed:23624058}.
CC   -!- CATALYTIC ACTIVITY: S-ubiquitinyl-[E2 ubiquitin-conjugating
CC       enzyme]-L-cysteine + [acceptor protein]-L-lysine = [E2 ubiquitin-
CC       conjugating enzyme]-L-cysteine + N(6)-ubiquitinyl-[acceptor
CC       protein]-L-lysine.
CC   -!- PATHWAY: Protein modification; protein ubiquitination.
CC   -!- SUBUNIT: Interacts with AGL. Interacts (via the NHL repeats) with
CC       EPM2A/laforin. Forms a complex with EPM2A/laforin and HSP70.
CC       Interacts with PRDM8 (PubMed:22961547).
CC       {ECO:0000269|PubMed:15930137, ECO:0000269|PubMed:17908927,
CC       ECO:0000269|PubMed:21505799, ECO:0000269|PubMed:22961547}.
CC   -!- INTERACTION:
CC       O95278:EPM2A; NbExp=7; IntAct=EBI-6426628, EBI-2506661;
CC       Q9WUA5:Epm2a (xeno); NbExp=12; IntAct=EBI-6426628, EBI-1040928;
CC   -!- SUBCELLULAR LOCATION: Endoplasmic reticulum. Nucleus.
CC       Note=Localizes at the endoplasmic reticulum and, to a lesser
CC       extent, in the nucleus.
CC   -!- TISSUE SPECIFICITY: Expressed in brain, cerebellum, spinal cord,
CC       medulla, heart, liver, skeletal muscle and pancreas.
CC       {ECO:0000269|PubMed:12958597}.
CC   -!- DOMAIN: The RING domain is essential for ubiquitin E3 ligase
CC       activity. {ECO:0000269|PubMed:15930137}.
CC   -!- DISEASE: Epilepsy, progressive myoclonic 2 (EPM2) [MIM:254780]: An
CC       autosomal recessive and severe form of adolescent-onset
CC       progressive epilepsy. Typically, as seizures increase in
CC       frequency, cognitive function declines towards dementia, and
CC       affected individuals die usually within 10 years after onset. EPM2
CC       occurs worldwide, but it is particularly common in the
CC       mediterranean countries of southern Europe and northern Africa, in
CC       southern India and in the Middle East. At the cellular level, it
CC       is characterized by accumulation of starch-like polyglucosans
CC       called Lafora bodies (LBs) that are most abundant in organs with
CC       the highest glucose metabolism: brain, heart, liver and skeletal
CC       muscle. Among other conditions involving polyglucosans, EPM2 is
CC       unique in that the inclusions are in neuronal dendrites but not
CC       axons and the forming polyglucosan fibrils are associated with the
CC       endoplasmic reticulum. {ECO:0000269|PubMed:12958597,
CC       ECO:0000269|PubMed:15781812, ECO:0000269|PubMed:15930137,
CC       ECO:0000269|PubMed:16021330, ECO:0000269|PubMed:18311786,
CC       ECO:0000269|PubMed:21505799}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- WEB RESOURCE: Name=The Lafora progressive myoclonus epilepsy
CC       mutation and polymorphism database;
CC       URL="http://projects.tcag.ca/lafora/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AY324850; AAQ19671.1; -; mRNA.
DR   EMBL; AL589723; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC103888; AAI03889.1; -; mRNA.
DR   EMBL; BC103889; AAI03890.1; -; mRNA.
DR   EMBL; BC103890; AAI03891.1; -; mRNA.
DR   EMBL; BK001510; DAA01954.1; -; mRNA.
DR   CCDS; CCDS4542.1; -.
DR   RefSeq; NP_940988.2; NM_198586.2.
DR   UniGene; Hs.348351; -.
DR   ProteinModelPortal; Q6VVB1; -.
DR   SMR; Q6VVB1; -.
DR   BioGrid; 132073; 16.
DR   IntAct; Q6VVB1; 13.
DR   MINT; MINT-8374086; -.
DR   STRING; 9606.ENSP00000345464; -.
DR   iPTMnet; Q6VVB1; -.
DR   PhosphoSitePlus; Q6VVB1; -.
DR   BioMuta; NHLRC1; -.
DR   DMDM; 50400890; -.
DR   PaxDb; Q6VVB1; -.
DR   PeptideAtlas; Q6VVB1; -.
DR   PRIDE; Q6VVB1; -.
DR   Ensembl; ENST00000340650; ENSP00000345464; ENSG00000187566.
DR   GeneID; 378884; -.
DR   KEGG; hsa:378884; -.
DR   UCSC; uc003ncl.2; human.
DR   CTD; 378884; -.
DR   DisGeNET; 378884; -.
DR   GeneCards; NHLRC1; -.
DR   GeneReviews; NHLRC1; -.
DR   HGNC; HGNC:21576; NHLRC1.
DR   HPA; HPA066030; -.
DR   MalaCards; NHLRC1; -.
DR   MIM; 254780; phenotype.
DR   MIM; 608072; gene.
DR   neXtProt; NX_Q6VVB1; -.
DR   OpenTargets; ENSG00000187566; -.
DR   Orphanet; 501; Lafora disease.
DR   PharmGKB; PA134916338; -.
DR   eggNOG; ENOG410ITF2; Eukaryota.
DR   eggNOG; ENOG410ZMHC; LUCA.
DR   GeneTree; ENSGT00730000111361; -.
DR   HOGENOM; HOG000113780; -.
DR   HOVERGEN; HBG052617; -.
DR   InParanoid; Q6VVB1; -.
DR   KO; K10602; -.
DR   OMA; PRNLPCG; -.
DR   OrthoDB; EOG091G08MU; -.
DR   PhylomeDB; Q6VVB1; -.
DR   TreeFam; TF331018; -.
DR   Reactome; R-HSA-3322077; Glycogen synthesis.
DR   UniPathway; UPA00143; -.
DR   GeneWiki; NHLRC1; -.
DR   GenomeRNAi; 378884; -.
DR   PRO; PR:Q6VVB1; -.
DR   Proteomes; UP000005640; Chromosome 6.
DR   Bgee; ENSG00000187566; -.
DR   CleanEx; HS_NHLRC1; -.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005783; C:endoplasmic reticulum; IEA:UniProtKB-SubCell.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IEA:Ensembl.
DR   GO; GO:0061630; F:ubiquitin protein ligase activity; IEA:Ensembl.
DR   GO; GO:0004842; F:ubiquitin-protein transferase activity; IDA:UniProtKB.
DR   GO; GO:0008270; F:zinc ion binding; IEA:InterPro.
DR   GO; GO:0006914; P:autophagy; IEA:UniProtKB-KW.
DR   GO; GO:0005978; P:glycogen biosynthetic process; TAS:Reactome.
DR   GO; GO:0031398; P:positive regulation of protein ubiquitination; IEA:Ensembl.
DR   GO; GO:0043161; P:proteasome-mediated ubiquitin-dependent protein catabolic process; IDA:UniProtKB.
DR   GO; GO:0000209; P:protein polyubiquitination; IDA:UniProtKB.
DR   CDD; cd00162; RING; 1.
DR   Gene3D; 2.120.10.30; -; 2.
DR   Gene3D; 3.30.40.10; -; 1.
DR   InterPro; IPR011042; 6-blade_b-propeller_TolB-like.
DR   InterPro; IPR013017; NHL_repeat_subgr.
DR   InterPro; IPR001841; Znf_RING.
DR   InterPro; IPR013083; Znf_RING/FYVE/PHD.
DR   InterPro; IPR017907; Znf_RING_CS.
DR   Pfam; PF14634; zf-RING_5; 1.
DR   SMART; SM00184; RING; 1.
DR   PROSITE; PS51125; NHL; 6.
DR   PROSITE; PS00518; ZF_RING_1; 1.
DR   PROSITE; PS50089; ZF_RING_2; 1.
PE   1: Evidence at protein level;
KW   Autophagy; Complete proteome; Disease mutation; Endoplasmic reticulum;
KW   Epilepsy; Metal-binding; Nucleus; Polymorphism; Reference proteome;
KW   Repeat; Transferase; Ubl conjugation pathway; Zinc; Zinc-finger.
FT   CHAIN         1    395       E3 ubiquitin-protein ligase NHLRC1.
FT                                /FTId=PRO_0000055980.
FT   REPEAT      113    157       NHL 1.
FT   REPEAT      161    204       NHL 2.
FT   REPEAT      205    245       NHL 3.
FT   REPEAT      248    300       NHL 4.
FT   REPEAT      301    349       NHL 5.
FT   REPEAT      350    393       NHL 6.
FT   ZN_FING      26     72       RING-type. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00175}.
FT   VARIANT      22     22       S -> R (in EPM2; does not significantly
FT                                alters the subcellular location as
FT                                compared to the wild-type).
FT                                {ECO:0000269|PubMed:18311786}.
FT                                /FTId=VAR_046387.
FT   VARIANT      26     26       C -> S (in EPM2; dbSNP:rs28940575).
FT                                {ECO:0000269|PubMed:12958597}.
FT                                /FTId=VAR_019482.
FT   VARIANT      33     33       F -> S (in EPM2; dbSNP:rs757759398).
FT                                {ECO:0000269|PubMed:12958597}.
FT                                /FTId=VAR_019483.
FT   VARIANT      46     46       C -> Y (in EPM2; compound heterozygote
FT                                with A-69; loss of interaction with
FT                                EPM2A; increased levels of PPP1R3C and
FT                                glycogen). {ECO:0000269|PubMed:21505799}.
FT                                /FTId=VAR_070793.
FT   VARIANT      67     67       E -> Q (in EPM2; dbSNP:rs779507031).
FT                                {ECO:0000269|PubMed:15781812}.
FT                                /FTId=VAR_046388.
FT   VARIANT      68     68       C -> Y (in EPM2).
FT                                {ECO:0000269|PubMed:15781812}.
FT                                /FTId=VAR_046389.
FT   VARIANT      69     69       P -> A (in EPM2; compound heterozygote
FT                                with Y-46; severely reduced interaction
FT                                with EPM2A; increased levels of PPP1R3C
FT                                and glycogen; dbSNP:rs28940576).
FT                                {ECO:0000269|PubMed:12958597,
FT                                ECO:0000269|PubMed:21505799}.
FT                                /FTId=VAR_019484.
FT   VARIANT      87     87       L -> P (in EPM2).
FT                                {ECO:0000269|PubMed:12958597}.
FT                                /FTId=VAR_019485.
FT   VARIANT     111    111       P -> L (common polymorphism;
FT                                dbSNP:rs10949483).
FT                                {ECO:0000269|PubMed:12958597,
FT                                ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|PubMed:16021330}.
FT                                /FTId=VAR_019486.
FT   VARIANT     126    126       L -> P (in EPM2; the mutant protein
FT                                targeted exclusively nucleus as compared
FT                                to predominantly cytoplasmic and
FT                                partially nuclear localization of the
FT                                wild-type protein).
FT                                {ECO:0000269|PubMed:18311786}.
FT                                /FTId=VAR_046390.
FT   VARIANT     146    146       D -> N (in EPM2; compound heterozygote
FT                                with P-261; severely reduced interaction
FT                                with EPM2A; increased levels of PPP1R3C
FT                                and glycogen; dbSNP:rs769301934).
FT                                {ECO:0000269|PubMed:12958597,
FT                                ECO:0000269|PubMed:21505799}.
FT                                /FTId=VAR_019487.
FT   VARIANT     153    153       I -> M (in EPM2).
FT                                {ECO:0000269|PubMed:16021330}.
FT                                /FTId=VAR_046391.
FT   VARIANT     160    160       C -> R (in EPM2; dbSNP:rs200595273).
FT                                {ECO:0000269|PubMed:16021330}.
FT                                /FTId=VAR_046392.
FT   VARIANT     198    198       I -> N (in EPM2; dbSNP:rs121917876).
FT                                {ECO:0000269|PubMed:15781812}.
FT                                /FTId=VAR_046393.
FT   VARIANT     219    219       W -> R (in EPM2).
FT                                {ECO:0000269|PubMed:16021330}.
FT                                /FTId=VAR_046394.
FT   VARIANT     233    233       D -> A (in EPM2).
FT                                {ECO:0000269|PubMed:15781812}.
FT                                /FTId=VAR_046395.
FT   VARIANT     245    245       D -> N (in EPM2).
FT                                {ECO:0000269|PubMed:16021330}.
FT                                /FTId=VAR_046396.
FT   VARIANT     253    253       R -> K (in EPM2).
FT                                {ECO:0000269|PubMed:16021330}.
FT                                /FTId=VAR_046397.
FT   VARIANT     261    261       L -> P (in EPM2; compound heterozygote
FT                                with N-146; loss of interaction with
FT                                EPM2A; increased levels of PPP1R3C and
FT                                glycogen). {ECO:0000269|PubMed:21505799}.
FT                                /FTId=VAR_070794.
FT   VARIANT     264    264       P -> H (in EPM2).
FT                                {ECO:0000269|PubMed:15781812}.
FT                                /FTId=VAR_046398.
FT   VARIANT     279    279       L -> P (in EPM2; significantly alters the
FT                                distribution of the protein; a great
FT                                majority of cells expressing the mutant
FT                                form formed perinuclear inclusion when
FT                                compared with the wild-type form).
FT                                {ECO:0000269|PubMed:18311786}.
FT                                /FTId=VAR_046399.
FT   VARIANT     294    295       Missing (in EPM2).
FT                                {ECO:0000269|PubMed:15781812}.
FT                                /FTId=VAR_046400.
FT   VARIANT     302    302       Q -> P (in EPM2; loss of interaction with
FT                                EPM2A; dbSNP:rs757858146).
FT                                {ECO:0000269|PubMed:12958597,
FT                                ECO:0000269|PubMed:15930137}.
FT                                /FTId=VAR_019488.
FT   VARIANT     308    308       D -> A (in EPM2; dbSNP:rs137852859).
FT                                {ECO:0000269|PubMed:15781812}.
FT                                /FTId=VAR_046401.
FT   MUTAGEN     280    280       E->K: Loss of interaction with EP2MA.
FT                                {ECO:0000269|PubMed:15930137}.
SQ   SEQUENCE   395 AA;  42293 MW;  3E8339D00165FBED CRC64;
     MAAEASESGP ALHELMREAE ISLLECKVCF EKFGHRQQRR PRNLSCGHVV CLACVAALAH
     PRTLALECPF CRRACRGCDT SDCLPVLHLI ELLGSALRQS PAAHRAAPSA PGALTCHHTF
     GGWGTLVNPT GLALCPKTGR VVVVHDGRRR VKIFDSGGGC AHQFGEKGDA AQDIRYPVDV
     TITNDCHVVV TDAGDRSIKV FDFFGQIKLV IGGQFSLPWG VETTPQNGIV VTDAEAGSLH
     LLDVDFAEGV LRRTERLQAH LCNPRGVAVS WLTGAIAVLE HPLALGTGVC STRVKVFSSS
     MQLVGQVDTF GLSLYFPSKI TASAVTFDHQ GNVIVADTSG PAILCLGKPE EFPVPKPMVT
     HGLSHPVALT FTKENSLLVL DTASHSIKVY KVDWG
//
